Equities Analysts Offer Predictions for LRMR FY2026 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Thursday, July 2nd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($1.60) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($1.29) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.22.

Other equities research analysts have also issued research reports about the company. Wedbush reduced their target price on Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Robert W. Baird cut their price target on Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, June 30th. Finally, JPMorgan Chase & Co. started coverage on Larimar Therapeutics in a research report on Wednesday, May 27th. They set an “overweight” rating and a $9.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $12.71.

Larimar Therapeutics Price Performance

LRMR stock opened at $3.29 on Tuesday. The company’s 50 day simple moving average is $3.62 and its 200-day simple moving average is $3.93. Larimar Therapeutics has a 12 month low of $2.71 and a 12 month high of $6.42. The firm has a market capitalization of $341.35 million, a PE ratio of -1.58 and a beta of 0.83.

Institutional Trading of Larimar Therapeutics

A number of hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after acquiring an additional 4,376 shares during the period. Coldstream Capital Management Inc. purchased a new position in shares of Larimar Therapeutics during the 3rd quarter worth $57,000. SG Americas Securities LLC purchased a new position in shares of Larimar Therapeutics during the 4th quarter worth $60,000. Sei Investments Co. boosted its holdings in shares of Larimar Therapeutics by 54.5% during the first quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after purchasing an additional 5,763 shares during the last quarter. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Larimar Therapeutics during the fourth quarter worth $87,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.